Finally, in 744 infants who underwent both genotyping and nasopharyngeal metabolome profiling, the authors [18] applied an integrated genetics–metabolomics analysis showing that genetically driven metabolites (e.g., docosapentaenoate (DPA), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol, sphingomyelin) are associated with asthma development and that there are genetic loci (e.g., ADORA1, MUC16) associated with both these metabolites and asthma susceptibility. Here, MUC16 is linked to asthma.